低度的复合激活因子VII通过逆转abelacimabin vitro诱导的粘弹性测试参数的变化来使凝血模式正常化
Yasser Khder1, Serge Côté2, Klaus Peter Hoffmann3
1Anthos Therapeutics, Cambridge, Massachusetts, USA.
Research and practice in thrombosis and haemostasis
|August 21, 2025
概括
低剂量的复合活性因子VIIa (rFVIIa) 有效地逆转了FXI/ FXIa抑制剂阿贝拉西马布的抗凝固作用. 这表明rFVIIa可以控制abelacimab治疗的患者的出血.
科学领域:
- 血液学
- 药理学
背景情况:
- 复合活性因子VIIa (rFVIIa) 用于治疗因子XI缺乏的出血.
- 阿贝拉西马布是一种具有抗凝固功能的XI/ XIA抑制剂.
研究的目的:
- 评估低剂量rFVIIa是否可以抵消abelacimab引起的凝血变化.
- 通过旋转血栓形成测量 (ROTEM) 来评估rFVIIa的疗效.
主要方法:
- 来自健康捐献者的全血被用abelacimab处理.
- 后来添加了rFVIIa或车辆.
- 使用ROTEM测量凝血参数 (凝血时间,凝血形成时间,α角).
主要成果:
- 阿贝拉西马布显著延长了凝血时间,并降低了α角.
- 低度的rFVIIa (0. 5 - 1μg/ ml) 逆转了这些abelacimab诱导的影响.
- 通过rFVIIa的加法将ROTEM参数规范化.
结论:
- 低剂量rFVIIa有效地纠正了abelacimab对凝血的影响.
- 在接受abelacimab治疗的患者中,rFVIIa是一种潜在的治疗选择.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Coagulation
374
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
374


